Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study

Johannes Oldenburg, Midori Shima, Rebecca Kruse-Jarres, Elena Santagostino, Johnny Mahlangu, Michaela Lehle, Nives Selak Bienz, Sammy Chebon, Elina Asikanius, Peter Trask, Maria Elisa Mancuso, Victor Jiménez-Yuste, Sylvia von Mackensen, Gallia G. Levy

Research output: Contribution to journalArticlepeer-review


Background: Data regarding management of pediatric persons with hemophilia A (PwHA) with factor VIII (FVIII) inhibitors are limited. This prospective noninterventional study (NCT02476942) evaluated annualized bleeding rates (ABRs), safety, and health-related quality of life (HRQoL) in pediatric PwHA with FVIII inhibitors. Procedure: PwHA aged <12 years with current FVIII inhibitors and high-titer inhibitor history were enrolled. Participants remained on usual treatment; no interventions were applied. Outcomes included ABR, safety, and HRQoL. Results: Twenty-four PwHA aged 2-11 years (median 7.5) were enrolled and monitored for 8.7-44.1 weeks (median 23.4). In the episodic (n = 10) and prophylactic (n = 14) groups, respectively, 121 of 185 (65.4%) and 101 of 186 (54.3%) bleeds were treated using activated prothrombin complex concentrate (aPCC) and/or recombinant activated FVII (rFVIIa). ABRs (95% confidence interval) were 19.4 (13.2-28.4) and 18.5 (14.2-24.0) for treated bleeds, and 32.7 (20.5-52.2) and 33.1 (22.4-48.9) for all bleeds, respectively. Most prophylactic group participants (92.9%) were prescribed aPCC; 50% adhered to their prescribed treatment regimen. Adherence to prophylactic rFVIIa was not assessed. Serious adverse events included hemarthrosis (12.5%) and mouth hemorrhage (12.5%); the most common nonserious adverse event was viral upper respiratory tract infection (12.5%). HRQoL showed functional impairment at baseline; scores remained stable throughout, with little intergroup variation. Conclusions: ABRs remained high in pediatric PwHA with inhibitors receiving standard treatment. This study demonstrates the need for more effective treatments, with reduced treatment burden, to prevent bleeds, increase prophylaxis adherence, and improve patient outcomes.

Original languageEnglish
Article numbere28474
JournalPediatric Blood and Cancer
Issue number10
Publication statusPublished - 2020


  • blood coagulation factor inhibitors
  • emicizumab
  • health-related quality of life
  • hemophilia A
  • noninterventional study

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology


Dive into the research topics of 'Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study'. Together they form a unique fingerprint.

Cite this